Previous close | 28.24 |
Open | 28.35 |
Bid | 24.07 x 100 |
Ask | 25.16 x 200 |
Day's range | 23.73 - 28.82 |
52-week range | 12.57 - 42.50 |
Volume | |
Avg. volume | 680,546 |
Market cap | 944.92M |
Beta (5Y monthly) | 1.06 |
PE ratio (TTM) | N/A |
EPS (TTM) | -4.75 |
Earnings date | 08 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 57.38 |
With the business potentially at an important milestone, we thought we'd take a closer look at Tarsus Pharmaceuticals...
IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that management will participate in the following conferences: William Blair Growth Stock Conference Jeff Farrow, Chief Financial and Chief Strategy Officer, will participate in an in-person fireside chat on Tuesday, June 4, 2024, at 1:20 p
Tarsus Pharmaceuticals, Inc. ( NASDAQ:TARS ) just released its latest first-quarter results and things are looking...